close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc
Search

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.05 -6.25

Neutraalne

Hinna uuendus 18. märts 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.04

Max

1.13

Põhinäitajad

By Trading Economics

Sissetulek

-124K

-32M

Müük

-372K

1.4M

Aktsiakasum

-0.27

Kasumimarginaal

-2,364.792

Töötajad

161

EBITDA

-13M

-42M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+99.12% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-39M

135M

Eelmine avamishind

7.3

Eelmine sulgemishind

1.05

Uudiste sentiment

By Acuity

42%

58%

147 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. märts 2026, 22:51 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

DJ

Loe

18. märts 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

DJ

Loe

18. märts 2026, 20:31 UTC

Tulu

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

DJ

Loe

18. märts 2026, 23:49 UTC

Market Talk
Uudisväärsed sündmused

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

DJ

Loe

18. märts 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

DJ

Loe

18. märts 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

DJ

Loe

18. märts 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

DJ

Loe

18. märts 2026, 22:36 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

DJ

Loe

18. märts 2026, 22:24 UTC

Tulu

AIA Group Announces New Share Buyback of $1.7B >1299.HK

DJ

Loe

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

DJ

Loe

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

DJ

Loe

18. märts 2026, 21:58 UTC

Tulu

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

DJ

Loe

18. märts 2026, 21:55 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

18. märts 2026, 21:55 UTC

Market Talk
Tulu

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

DJ

Loe

18. märts 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

DJ

Loe

18. märts 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

DJ

Loe

18. märts 2026, 21:00 UTC

Uudisväärsed sündmused

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

DJ

Loe

18. märts 2026, 20:58 UTC

Tulu

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

DJ

Loe

18. märts 2026, 20:41 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Loe

18. märts 2026, 20:29 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Loe

18. märts 2026, 20:25 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

DJ

Loe

18. märts 2026, 20:17 UTC

Tulu

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

DJ

Loe

18. märts 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

DJ

Loe

18. märts 2026, 20:09 UTC

Tulu

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

DJ

Loe

18. märts 2026, 20:07 UTC

Tulu

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

DJ

Loe

18. märts 2026, 20:06 UTC

Tulu

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

DJ

Loe

18. märts 2026, 20:04 UTC

Tulu

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

DJ

Loe

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

DJ

Loe

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Gross Margin About 81% >MU

DJ

Loe

18. märts 2026, 20:03 UTC

Tulu

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

99.12% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD  99.12%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

0

Osta

4

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

No Evidence

There are no events.

Sentiment

By Acuity

147 / 351 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

916.49

↓-1.52%

JNJ

Johnson and Johnson

237.15

↓-0.37%

ABBV

AbbVie Inc

208.28

↓-5.27%

NVS

Novartis AG

149.76

↓-3.06%

AZN

AstraZeneca PLC

188.42

↓-1.47%
help-icon Live chat